secwatch.observer — SEC 8-K summary ====================================== Issuer: Passage BIO, Inc. (PASG) CIK: 0001787297 Form: 8-K Filed at: 2026-11-18T21:15:33+00:00 Accession: 0001140361-26-044734 Event type: regulatory Sentiment: negative Materiality: 0.62 Item codes: 3.01 LLM model: deepseek-v4.1-flash:cloud@v2 Passage Bio gets Nasdaq deficiency notice; stockholders' equity $50K vs $2.5M minimum -------------------------------------------------------------------------------- - Nasdaq Rule 5550(b)(1) requires $2.5M minimum stockholders' equity; Passage Bio reported $50,000 at Sept 30, 2026 and fails the market-value and net-income alternatives. - Letter from Nasdaq Listing Qualifications dated Nov 12, 2026 has no immediate effect; PASG continues trading on the Nasdaq Capital Market. - Company expects the pending Remix Therapeutics mergers (A&R agreement dated Sept 2, 2026, amended Oct 5, 2026) to restore compliance on close. - Upon closing, Passage Bio will rename itself Remix Therapeutics, Inc. and trade under symbol RMTX; Nasdaq listing approval is a remaining closing condition. - If the mergers are not completed within the Nasdaq-provided period, the company intends to submit a plan to regain compliance. Source: EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000114036126044734/0001140361-26-044734-index.htm Primary doc: https://www.sec.gov/Archives/edgar/data/1787297/000114036126044734/ef20085890_8k.htm HTML page: https://secwatch.observer/filing/0001140361-26-044734 License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer